Literature DB >> 19922767

GAS6/Mer axis regulates the homing and survival of the E2A/PBX1-positive B-cell precursor acute lymphoblastic leukemia in the bone marrow niche.

Yusuke Shiozawa1, Elisabeth A Pedersen, Russell S Taichman.   

Abstract

OBJECTIVE: Despite improvements in current combinational chemotherapy regimens, the prognosis of the (1;19)(q23;p13) translocation (E2A/PBX1)-positive B-cell precursor acute lymphoblastic leukemia (ALL) is poor in pediatric leukemia patients.
MATERIALS AND METHODS: In this study, we examined the roles of growth arrest-specific-6 (GAS6)/Mer axis in the interactions between E2A/PBX1-positive B-cell precursor ALL cells and the osteoblastic niche in the bone marrow.
RESULTS: Data show that primary human osteoblasts secrete GAS6 in response to the Mer-overexpressed E2A/PBX1-positive ALL cells through mitogen-activated protein kinase signaling pathway and that leukemia cells migrate toward GAS6 using pathways activated by Mer. Importantly, GAS6 supports survival and prevents apoptosis from chemotherapy of E2A/PBX1-positive ALL cells by inducing dormancy.
CONCLUSIONS: These data suggest that GAS6/Mer axis regulates homing and survival of the E2A/PBX1-positive B-cell precursor ALL in the bone marrow niche. Copyright 2010 ISEH - Society for Hematology and Stem Cells. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19922767      PMCID： PMC2815170          DOI： 10.1016/j.exphem.2009.11.002

Source DB:  PubMed          Journal:  Exp Hematol        ISSN： 0301-472X            Impact factor:   3.084


  37 in total

1.  SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells.

Authors:  Mark J Kiel; Omer H Yilmaz; Toshihide Iwashita; Osman H Yilmaz; Cox Terhorst; Sean J Morrison
Journal:  Cell       Date:  2005-07-01       Impact factor: 41.582

2.  Analysis of Gas6 in human platelets and plasma.

Authors:  Istvan Balogh; Sassan Hafizi; Jonas Stenhoff; Karin Hansson; Björn Dahlbäck
Journal:  Arterioscler Thromb Vasc Biol       Date:  2005-03-24       Impact factor: 8.311

3.  Stromal cells regulate survival of B-lineage leukemic cells during chemotherapy.

Authors:  R E Mudry; J E Fortney; T York; B M Hall; L F Gibson
Journal:  Blood       Date:  2000-09-01       Impact factor: 22.113

4.  Soluble Axl is generated by ADAM10-dependent cleavage and associates with Gas6 in mouse serum.

Authors:  Vadim Budagian; Elena Bulanova; Zane Orinska; Erwin Duitman; Katja Brandt; Andreas Ludwig; Dieter Hartmann; Greg Lemke; Paul Saftig; Silvia Bulfone-Paus
Journal:  Mol Cell Biol       Date:  2005-11       Impact factor: 4.272

5.  Multiple roles for the receptor tyrosine kinase axl in tumor formation.

Authors:  Sacha J Holland; Mark J Powell; Christian Franci; Emily W Chan; Annabelle M Friera; Robert E Atchison; John McLaughlin; Susan E Swift; Erlina S Pali; George Yam; Stephen Wong; Joe Lasaga; Mary R Shen; Simon Yu; Weiduan Xu; Yasumichi Hitoshi; Jakob Bogenberger; Jacques E Nör; Donald G Payan; James B Lorens
Journal:  Cancer Res       Date:  2005-10-15       Impact factor: 12.701

6.  Identification of the haematopoietic stem cell niche and control of the niche size.

Authors:  Jiwang Zhang; Chao Niu; Ling Ye; Haiyang Huang; Xi He; Wei-Gang Tong; Jason Ross; Jeff Haug; Teri Johnson; Jian Q Feng; Stephen Harris; Leanne M Wiedemann; Yuji Mishina; Linheng Li
Journal:  Nature       Date:  2003-10-23       Impact factor: 49.962

7.  Osteoblastic cells regulate the haematopoietic stem cell niche.

Authors:  L M Calvi; G B Adams; K W Weibrecht; J M Weber; D P Olson; M C Knight; R P Martin; E Schipani; P Divieti; F R Bringhurst; L A Milner; H M Kronenberg; D T Scadden
Journal:  Nature       Date:  2003-10-23       Impact factor: 49.962

8.  Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia.

Authors:  Takuya Matsunaga; Naofumi Takemoto; Tsutomu Sato; Rishu Takimoto; Ikuta Tanaka; Akihito Fujimi; Takehide Akiyama; Hiroyuki Kuroda; Yutaka Kawano; Masayoshi Kobune; Junji Kato; Yasuo Hirayama; Sumio Sakamaki; Kyuhei Kohda; Kensuke Miyake; Yoshiro Niitsu
Journal:  Nat Med       Date:  2003-08-03       Impact factor: 53.440

9.  Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling.

Authors:  Eng-Juh Yeoh; Mary E Ross; Sheila A Shurtleff; W Kent Williams; Divyen Patel; Rami Mahfouz; Fred G Behm; Susana C Raimondi; Mary V Relling; Anami Patel; Cheng Cheng; Dario Campana; Dawn Wilkins; Xiaodong Zhou; Jinyan Li; Huiqing Liu; Ching-Hon Pui; William E Evans; Clayton Naeve; Limsoon Wong; James R Downing
Journal:  Cancer Cell       Date:  2002-03       Impact factor: 31.743

10.  Mantle cell lymphomas express a distinct genetic signature affecting lymphocyte trafficking and growth regulation as compared with subpopulations of normal human B cells.

Authors:  Sara Ek; Carl-Magnus Högerkorp; Michael Dictor; Mats Ehinger; Carl A K Borrebaeck
Journal:  Cancer Res       Date:  2002-08-01       Impact factor: 12.701
View more
  34 in total

Review 1.  Macrophage-tumor crosstalk: role of TAMR tyrosine kinase receptors and of their ligands.

Authors:  Thomas Schmidt; Isabel Ben-Batalla; Alexander Schultze; Sonja Loges
Journal:  Cell Mol Life Sci       Date:  2011-11-11       Impact factor: 9.261

Review 2.  A hostel for the hostile: the bone marrow niche in hematologic neoplasms.

Authors:  Daniela S Krause; David T Scadden
Journal:  Haematologica       Date:  2015-11       Impact factor: 9.941

3.  Bone Marrow Microenvironment Niche Regulates miR-221/222 in Acute Lymphoblastic Leukemia.

Authors:  Blake S Moses; Rebecca Evans; William L Slone; Debbie Piktel; Ivan Martinez; Michael D Craig; Laura F Gibson
Journal:  Mol Cancer Res       Date:  2016-06-29       Impact factor: 5.852

4.  Autocrine and Paracrine Interactions between Multiple Myeloma Cells and Bone Marrow Stromal Cells by Growth Arrest-specific Gene 6 Cross-talk with Interleukin-6.

Authors:  Miki Furukawa; Hiroshi Ohkawara; Kazuei Ogawa; Kazuhiko Ikeda; Koki Ueda; Akiko Shichishima-Nakamura; Emi Ito; Jun-Ichi Imai; Yuka Yanagisawa; Reiko Honma; Shinya Watanabe; Satoshi Waguri; Takayuki Ikezoe; Yasuchika Takeishi
Journal:  J Biol Chem       Date:  2017-01-31       Impact factor: 5.157

Review 5.  Molecular pathways: niches in metastatic dormancy.

Authors:  Kenji Yumoto; Matthew R Eber; Janice E Berry; Russell S Taichman; Yusuke Shiozawa
Journal:  Clin Cancer Res       Date:  2014-04-22       Impact factor: 12.531

Review 6.  TYRO3: A potential therapeutic target in cancer.

Authors:  Pei-Ling Hsu; Jonathan Jou; Shaw-Jenq Tsai
Journal:  Exp Biol Med (Maywood)       Date:  2019-02-02

Review 7.  The TAM family: phosphatidylserine sensing receptor tyrosine kinases gone awry in cancer.

Authors:  Douglas K Graham; Deborah DeRyckere; Kurtis D Davies; H Shelton Earp
Journal:  Nat Rev Cancer       Date:  2014-12       Impact factor: 60.716

8.  The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia.

Authors:  Katherine A Minson; Catherine C Smith; Deborah DeRyckere; Clara Libbrecht; Alisa B Lee-Sherick; Madeline G Huey; Elisabeth A Lasater; Gregory D Kirkpatrick; Michael A Stashko; Weihe Zhang; Craig T Jordan; Dmitri Kireev; Xiaodong Wang; Stephen V Frye; H Shelton Earp; Neil P Shah; Douglas K Graham
Journal:  JCI Insight       Date:  2016-03

Review 9.  RANK-mediated signaling network and cancer metastasis.

Authors:  Gina Chia-Yi Chu; Leland W K Chung
Journal:  Cancer Metastasis Rev       Date:  2014-09       Impact factor: 9.264

10.  UNC2025, a MERTK Small-Molecule Inhibitor, Is Therapeutically Effective Alone and in Combination with Methotrexate in Leukemia Models.

Authors:  Deborah DeRyckere; Alisa B Lee-Sherick; Madeline G Huey; Amanda A Hill; Jeffrey W Tyner; Kristen M Jacobsen; Lauren S Page; Gregory G Kirkpatrick; Fatma Eryildiz; Stephanie A Montgomery; Weihe Zhang; Xiaodong Wang; Stephen V Frye; H Shelton Earp; Douglas K Graham
Journal:  Clin Cancer Res       Date:  2016-09-20       Impact factor: 12.531
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.